Trial Profile
Clinical study of Rituximab for inhibition of antibody mediated rejection in ABO-incompatible kidney transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Oct 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- 27 Oct 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 04 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 04 Nov 2011 New trial record